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Abstract
Objective—To compare the prevalence of diagnosed ocular disease and eye disease treatment 
between VA patients with and without serious mental illness (SMI).
Methods—Retrospective comparison of diagnosed ocular disease and treatment prevalence 
among patients with and without diagnosed SMI in fiscal year (FY) 2011 in the VA Capitol Health 
Care System (VISN 5).
Results—We identified 6,462 VA patients with SMI and 137,933 without SMI. The prevalence 
of diagnosed ocular disease was 22.7% in SMI patients and 35.4% in non-SMI patients (P 
<0.001). Those with serious mental illness had a higher prevalence of glaucoma (10.2% vs. 7.1% 
P < 0.0001), cataract (12.6% vs. 9.2% P < 0.0001), and dry eye (4.0% vs. 2.7% P < 0.0001). 
34.3% of SMI subjects had been seen in ophthalmology or optometry vs. 23.0% of controls (P < 
0.0001).
Conclusion—VA patients with SMI have a greater prevalence of diagnosed ocular disease, 
particularly cataract, glaucoma, and dry eye. While SMI patients utilize eye care services at a 
higher rate than the general VA population, the majority of subjects with serious mental illness do 
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not get recommended annual eye examinations. More consistent annual ocular screening among 
VA patients with SMI may be indicated.
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1. Introduction
Compared to others of similar age, individuals with serious mental illness (SMI) are at 
potentially higher risk for ocular disease due to their greater exposure to certain risk factors, 
including cigarette smoking1, metabolic syndrome and diabetes2, and antipsychotic 
medications, which predispose them to both cataract 3 and dry eye4. Indeed, prior research 
has shown that such individuals have a higher prevalence of visual impairment than the 
general population5, and smaller studies conducted without comparison groups indicate that 
this population has a high prevalence of ocular disease6,7. For this reason, individuals with 
schizophrenia are recommended to have eye exams every two years until age forty after 
which the recommendation is for yearly examinations8,9. To our knowledge, no prior work 
has evaluated the prevalence of diagnosed ocular diseases in any large and generalizable 
sample of individuals with SMI. Whereas individuals with SMI are known to have a higher 
rate of visual impairment, the prevalence of specific diagnosed ocular diseases and receipt of 
treatment for ocular disease have not been studied in large and generalizable U.S. population 
samples.
The Veteran’s Administration (VA) treats greater than a quarter of a million patients with 
serious mental illness annually10. The number of VA patients with SMI has increased 
steadily in the past ten years and is projected to continue to increase with the influx of 
Veterans from Operations Enduring Freedom/Operation Iraqi Freedom and continuing 
operations11. The rate of age-related eye disease is similarly increasing in the VA 
population.12 Given the high prevalence of serious mental illness and the extensive 
diagnostic, procedure, pharmacy, and utilization data available, the VA system is an ideal 
place to study the diagnosed prevalence of ocular disease and utilization of eye care services 
in this potentially high risk population. The purpose of this study is to assess the prevalence 
of diagnosed ocular disease in VA patients with SMI and to assess the utilization of clinic 
visits, medications, and cataract extractions as compared to the general VA population.
2. Methods
Data for the study were obtained from the VA pharmacy and health care utilization databases 
for patients in the VA Capitol Health Care Network (VISN 5), the mid-Atlantic service 
region that encompasses Maryland and Washington DC, northern Virginia, and northeastern 
West Virginia. These areas are served by four VA hospitals and by a network of freestanding 
VA hospital-affiliated outpatient medical clinics. This study was approved by the 
Institutional Review Board of the University of Maryland School of Medicine and the VA 
Maryland Health Care System (VAMHCS) Research and Development Committee.
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2.1 Sample Selection
To ensure that we included veterans that regularly followed up in the VA system, our 
analysis included all VA patients in the mid-Atlantic service region who had at least two 
contacts with the VA system in FY 2011. We divided this group between those with and 
without SMI. Patients with serious mental illness were identified using an algorithm 
established by the VA Serious Mental Illness Treatment Resource and Evaluation Center 
(SMITREC).10 Using the diagnostic codes from inpatient and outpatient encounter data, we 
identified all VA patients with diagnoses of schizophrenia/schizoaffective disorder (ICD-9 
codes 295.0-295.4 or 295.6-9), bipolar disorder (ICD-9 codes 296.0-1 or 296.4-8), or other 
diagnoses of psychosis (297.0-3, 297.8-9, 298.0-4, or 298.8-9) during fiscal year 201110. 
Patients with SMI were included provided they had at least one qualifying diagnosis in 
inpatient or outpatient data for FY 2011. Controls were all patients who had at least two 
contacts with the VA system in FY2011 who were not determined to have SMI using the 
above criteria.
2.2 Variables/Risk Factors
Demographic and socioeconomic characteristics included age, race, gender, income, marital 
status, service connection, prescription copay, homelessness, which facility the patient was 
seen. Patients were classified as diabetic if they had had ≥2 inpatient or outpatient records 
with diagnostic codes of 250.0–250.9, 357.2, 362.0, or 366.41, a previously validated 
methodology.13
Ophthalmic diagnoses were abstracted from ICD-9 codes assigned at each eye clinic visit. 
We specified ophthalmic diagnoses of interest, focusing on cataract, ophthalmic 
complications of diabetes, and glaucoma. Dry eye syndrome was also examined. Cataract 
included all forms of cataract specified by the ICD-9 code 366.xx. Ophthalmic 
complications of diabetes were specified with ICD-9 codes for ophthalmic manifestations of 
diabetes (250.5x), nonproliferative (362.01, 362.03, 362.04, 362.05, 362.06) and 
proliferative diabetic retinopathy (362.02), and diabetic macular edema (362.07). Glaucoma 
included all forms of glaucoma, including glaucoma suspect and the ICD-9 codes included 
were 365.xx. Dry Eye Syndrome was also determined by ICD-9 codes (370.33, 370.34, 
372.53, 375.15, and 710.20). We assessed the diagnosed prevalence of all ophthalmic 
diagnoses by using ICD-9 codes for all ophthalmic diagnoses (360.xx – 379.xx, 250.5x, 
951.0, 951.1, 951.3). Eye care utilization was assessed by frequency of clinic visits to 
ophthalmology or optometry (VA clinic stop codes 407 and 408), prescription fills, and 
procedure utilization. Ocular medications were categorized using the VA pharmacy 
classification system 14 and we specifically assessed if a VA patient had been prescribed at 
least one prescription fill of glaucoma medications (OP109), eye lubricants for dry eye 
(OP500), and overall ocular medication use (OPXXX). Frequency of cataract surgeries 
performed was determined from CPT codes (66850-66984) and ICD-9 procedure codes 
(13.2x-13.5x). Service connection in the VA system indicates that the diagnosis being 
treated is connected to the veterans’ service and care related to that illness is covered by the 
VA insurance system. VA patients with greater than 50% service connection do not pay a 
prescription copay.
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2.3 Statistical Analysis
Patients with SMI were compared to controls for all collected variables. For categorical 
variables, chi squared analysis was used, and for continuous variables independent student t-
test was utilized. For ophthalmic diagnoses of interest, we stratified the diagnoses by age in 
five year intervals. Analysis of the prevalence of ophthalmic complications of diabetes was 
done for the entire sample as well as limited to patients diagnosed with diabetes. 
Multivariable analysis was completed for both ophthalmic diagnoses of interest and 
ophthalmic utilization, controlling for age, race, and presence of diabetes. Glaucoma, 
cataract, eye clinic utilization, medication utilization, and cataract surgery utilization were 
dependent variables and age, race, and presence of diabetes were independent variables. 
Ophthalmic complications of diabetes were assessed separately only among those who had a 
diagnosis of diabetes with independent variables of age and race.
3. Results
In FY 2011 there were 6,462 Veterans with serious mental illness (4.5 % of all veterans) 
treated in the VA Capitol Health Care Network and 137,933 Veterans treated who did not 
have serious mental illness. 2,287 (35.4%) patients with SMI versus 31,324 (22.7%) control 
patients had diagnosed ocular disease (P < 0.001). SMI patients were younger, more likely 
to be female, more likely to be African American, poorer, less likely to be married, had a 
high rate of service connection (and therefore lower prescription copay), more likely to be 
homeless, more likely to be treated in the VAMHCS, and more likely to be diabetic (Table 
1).
When ICD-9 code 367.xx, disorders of refraction and accommodation were removed, the 
prevalence of diagnosed ocular disease in patients with SMI and controls was 28.7% and 
19.7% respectively (P < 0.0001). Diagnosed glaucoma had a prevalence of 10.2% in the SMI 
group and 7.1% in the control group (P < 0.001) (Table 2). Similarly, diagnosed cataract had 
a prevalence of 12.6% and 9.2% in the SMI and control groups respectively (P < 0.001). 258 
(4.0%) VA patients with SMI had dry eye syndrome compared to 3750 (2.7%) in the control 
group (P <.0001).
When cataract, glaucoma, and ophthalmic complications of diabetes were stratified by age 
(Table 3), patients with SMI had a higher prevalence of cataract and glaucoma in nearly 
every age category as compared to controls (Table 4). There was no significant difference in 
the two samples in any age group for ophthalmic complications of diabetes. When restricting 
this analysis of ophthalmic complications of diabetes to patients with diabetes, 135 (2.1%) 
diabetic patients with serious mental illness had ophthalmic complications of diabetes as 
compared to 2,773 (2.0%) of diabetic controls (P = 0.660).
Patients with SMI utilized eye care clinics more than those without SMI; 34.3% were seen in 
either optometry or ophthalmology clinics compared with 23.0% of those without SMI (P < 
0.0001). Among subjects greater than 40 years of age, 37.6% were seen in eye clinic in 
FY2011 compared to 25.3% of those without SMI (P < 0.0001). On average, SMI patients 
had 0.6 +/− 1.4 visits to ophthalmology or optometry clinics in FY 2011 compared to 0.5+/
− 1.3 for controls (P < 0.0001). Overall, 55 (0.9%) patients with SMI underwent cataract 
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extraction in FY2011 compared to 934 (0.7%) controls (P = 0.097). Conversely, patients 
with SMI had higher utilization of ophthalmic medications; 16.1% versus 9.9% of Controls 
(P < 0.0001). On average SMI patients had 1.0 +/− 4.1 ocular prescription fills in the study 
period compared to 0.6 +/− 3.0 for controls (P < 0.0001). Patients with SMI had higher 
utilization for glaucoma medications, lubricants, and all ophthalmic medications (Table 4).
In a multivariable regression analysis that controlled for age, race, and diabetic status, SMI 
was associated with a higher odds of having a diagnosis of both cataract (OR: 1.30, 95% CI 
1.19, 1.42, P < 0.0001) and glaucoma (OR: 1.38, 95% CI 1.27, 1.49, P < 0.0001). Among 
patients with diabetes, patients with SMI had lower odds of being diagnosed with 
ophthalmic complications of diabetes (OR: 0.73, 95% CI 0.61, 0.88, P<0.0001). Using 
multivariable regression, controlling for age, race, and diabetes, SMI was associated with a 
higher odds of eye clinic utilization (OR: 1.45, 95% CII 1.37, 1.54, p < 0.0001), medication 
utilization (OR: 1.61, 95% CI 1.5, 1.73, p < 0.0001), but not cataract surgery (OR: 1.14, 
95% CI 0.86, 1.5, p = 0.36).
4. Discussion
This is the first study to examine the prevalence of diagnosed ocular conditions using 
administrative data in a sample of individuals with serious mental illness. VA patients with 
SMI have a higher prevalence of diagnosed ocular disease and have higher utilization of 
clinical eye care and ocular medications but do not have higher utilization of cataract 
surgery. Whether increased diagnosis is due to increased utilization since SMI patients may 
be more likely to be referred for ocular examination or due to increased prevalence of eye 
disease in this population due to environmental factors cannot be determined in the present 
study.
In a large, population-based sample in Finland, Viertio et al found that individuals with 
schizophrenia had five-fold higher odds of having visual impairment at distance and six-fold 
higher odds of having decreased near vision. They further found that those with 
schizophrenia were significantly less likely to have had their vision examined in the prior 5 
years, and recommended regular ocular evaluations as part of physical monitoring for 
patients with psychotic disorders5. This is consistent with the recommendations of the expert 
panel at the Mount Sinai Conference in 2002. This group of experts in schizophrenia, 
obesity, diabetes, cardiology, endocrinology, and ophthalmology met at the Mount Sinai 
School of Medicine in New York in 2002 to develop recommendations for the systemic 
monitoring of patients with schizophrenia. They noted that “a reasonable frequency for 
visual (including slit lamp) monitoring is yearly for all patients with schizophrenia older 
than age 40 and every 2 years for younger patients9.” SMI patients have similar risk factors 
for ocular disease as those with psychosis. Given that the vast majority of our patients were 
older than 40, our study supports this recommendation for annual screening.
Our study found a high prevalence of cataract and glaucoma in severely mentally ill patients 
confirming findings of previous, smaller studies. In a study of 23 inpatients with 
schizophrenia, Smith et al found that nearly 70% had untreated visual problems. 5 patients 
(21.7%) had lens opacities or cataracts and 1 (4.3%) had glaucoma6. Maino et al. 
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retrospectively reviewed records of 48 patients with mental illness and found the prevalence 
of cataract and glaucoma to be 8.7% and 10.8% respectively7. The present study relied on 
coding and this may explain why rates were generally lower in the previous studies. Also, 
the age distributions were not the same, as our sample was generally older than these prior 
studies.
The higher rate of diagnosed cataract and glaucoma in patients with SMI exists despite the 
fact that these patients are younger overall than controls. When the data are age-stratified, 
patients with SMI had a higher prevalence of glaucoma and cataract in all age categories. 
One cannot conclude from these data whether or not the prevalence of these conditions is 
truly higher in the SMI population, however. Those with serious mental illness have a higher 
utilization of eye care clinic services as well as ocular medications in the VA system. This is 
consistent with national VA data that shows that SMI patients had more medical outpatient 
clinic visits and overall outpatient clinic visits than the general VA population per year10,15
The higher rate of glaucoma could in part be explained by the higher propensity of those 
with SMI to have metabolic syndrome16,17, as diabetes has been described as a potential risk 
factor for glaucoma18. However, the higher risk of glaucoma associated with diabetes is 
small and unlikely to fully explain the differences seen. Long term medication use may also 
play a role. Interestingly, recent evidence has shown that non-diabetic patients with 
schizophrenia have thinner nerve fiber layer than age-matched controls19, 20. This may 
predispose patients to glaucoma or may make it appear as though these patients have 
glaucoma; both require further study. The higher rate of diagnosed cataract in patients with 
SMI may be due to increased eye service utilization in this population, higher rate of 
diabetes,16,17 exposure to cataractogenic antipsychotic medications3, or a combination of 
these factors. In a case-control study, McCarty et al found that the prevalence of anterior 
subcapsular cataract in patients with schizophrenia was 26%3. While Quetiapine has been 
implicated in cataract formation, this association is controversial 21-23.
While the prevalence of Type 2 diabetes in individuals with SMI is two to three times higher 
than in the general population,24 we found SMI to be protective of ophthalmic complications 
of diabetes in our sample. This is consistent with prior work showing that individuals with 
both psychosis and diabetes have a lower risk for diabetic complications.25 Though not 
completely understood, this may be because individuals with SMI have both better 
adherence to medication to treat diabetes as well as better glycemic control.26-29 Indeed. 
improving diabetes care for all VA patients would likely result in lower rates of diabetic 
retinopathy.
Patients with SMI were also found to have a higher rate of dry eye syndrome (4.0%) than 
controls (2.7%). This is consistent with the finding that VA patients on psychiatric 
medications have a higher risk for dry eye syndrome, second only to antihistamines4, and 
may be due to their anticholinergic effect. This would also explain why 9.5% of affected VA 
patients used medications from the category Eye Wash/Lubricants, which are dispensed 
through the VA pharmacy.
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We also found that although patients with serious mental illness had a higher prevalence of 
cataract and higher utilization of clinic services as well as medications, they had an equal 
rate of utilization of cataract surgery, the most common ophthalmic surgery. This may be 
due to the higher utilization of eye care services among SMI patients creating a lead-time 
bias, where cataract is diagnosed earlier as compared to controls, prior to the need for 
surgical intervention. It may also be due to physician reluctance to do procedures on SMI 
patients. Such bias has been shown in surveys of physicians 30 and may play a role in 
disparities of care in this population. 31-32 One can hypothesize that ophthalmologists may 
perceive that patients with SMI present a higher surgical risk due to potential hygiene issues 
or eye rubbing, despite that fact that there is no published evidence to support such 
perceptions.
Patients with SMI had a higher utilization of eye care, which reflects the VA’s commitment 
to health care for this population. Greater than 90% of patients with SMI in our study were 
“Service connected” indicating that their care was in part or completely covered by the VA 
system. Furthermore, a significant number of them did not pay a prescription copay. This 
indicates that these patients have greater access to care than the overall VA population and 
may explain the higher utilization. Still, only 37.6 % of patients with SMI greater than 40 
had been seen in optometry or ophthalmology in FY 2011. This rate is quite low given the 
recommendation that individuals with schizophrenia over 40 should have yearly eye exams. 
While this may be due to a general problem in VA service delivery it points to the need for 
greater awareness among treatment healthcare professionals about this recommendation, The 
limitations of this study are its retrospective design and focus on one region of the country. 
While it is possible that there is regional variation, our sample was ethnically diverse and 
included urban, suburban, and rural areas. The study relied solely on ICD-9 diagnosis codes 
to determine prevalence of ocular disease, so there may have been errors in diagnosis, 
reporting, or coding. Prior studies have shown that VA outpatient data, specifically for 
ophthalmology clinical data has a high level of agreement with the medical record33. Our 
estimates of the increased risk of eye conditions among SMI subjects may be lower than one 
would find if comparison were made to non-veteran populations as control patients in this 
study likely included patients who did not have SMI as defined here but may have had other 
mental illnesses and may have had exposure to similar risk factors placing them at higher 
risk of ocular disease. Associations between diagnosis and utilization may be confounded by 
unrecognized illness or outcome-related factors associated with VA service utilization. 
Differences in symptom reporting between patients with SMI and those without SMI may 
affect utilization of services, but would not affect the rate of screening, which is noted to be 
relatively low.
VA patients with a SMI have a higher prevalence of diagnosed ocular disease, particularly 
cataract, glaucoma, and dry eye, than patients without a psychotic disorder. They also have 
greater utilization of eye care services, on average. Nevertheless, the majority of VA patients 
with serious mental illness do not receive yearly eye screenings. Further study is required to 
determine the effect of increased utilization of eye care services on estimated disease 
prevalence. These results indicate a potential need for more consistent annual ocular 
screening of veterans and other individuals with SMI.
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Highlights
VA patients with serious mental illness have a significantly higher rate of 
diagnosed ocular disease than those without SMI.
VA patients with SMI have a higher prevalence of diagnosed glaucoma, 
cataract, and dry eye as compared to those without serious mental illness.
VA patients with SMI utilize eye care services at a higher rate than the those 
without SMI, the majority do not get recommended annual eye 
examinations.
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Table 1
Demographics of Veterans With and Without SMI
Variable
SMI
(N=6,462)
Control
(N=137,933)
Age* 54.7 ± 13.8 60.0 ± 17.0
Gender* Male 5,573(86.4%) 121,674(88.2%)
Race* White
African American
Other
2,938(48.9%)
2,994(49.8%)
78(1.3%)
15,939(53.4%)
13,404(44.9%)
527(1.8%)
Income* Mean 18,727.0 ± 37,077.0 32,696.1 ± 59,154.1
Marital Status* Married 1,752(28.7%) 66,287(56.0%)
Service Connection* 5,885(91.9%) 93,043(73.2%)
Exempt from Prescription
Copay*
2,458(38.4%) 27,697(21.8%)
Homelessness* 1,192(18.4%) 4,589(3.3%)
VISN 5 facility* Washington DC & W.
Virginia
Maryland
3,769(58.8%)
2,644(41.2%)
89,964(66.3%)
45,651(33.7%)
Diabetes*- Yes 1,597(24.7%) 26,067(18.9%)
Any Ophthalmic diagnosis* Yes 2,287(35.4%) 31,324(22.7%)
*Statistically significant difference P < 0.01
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Table 2
Select ocular diagnoses among Veterans with and without SMI
Disease
Category
ICD-9
Code
SMI
(N=6,462)
Control
(N=137,933)
Glaucoma* 365.xx 658(10.2%) 9,773(7.1%)
Ophthalmic
Complications of
Diabetes
250.5x,
362.01,
362.02,
362.03,
362.04,
362.05,
362.06,
362.07,
135(2.1%) 2,773(2.0%)
Cataract* 366.xx 817(12.6%) 12,712(9.2%)
*Statistically significant difference P < 0.01
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Table 4
Ophthalmic medication utilization among veterans with and without SMI
Label
SMI
(N=6,462)
Controls
(N=137,933)
Antiglaucoma* 283(4.4%) 4,905(3.6%)
Eye Washes/Lubricants* 616(9.5%) 6,764(4.9%)
Any Ophthalmic Medication* 1,040(16.1%) 13,687(9.9%)
Mean number of Ophthalmic medication fills* 1.0 ± 4.1 0.6 ± 3.0
*Statistically significant difference P < 0.01
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